Development and optimization of orodispersible tablets using solid dispersion of Telmisartan

Joshi Ramakant*, Akram Wasim, Garud Navneet, Dubey Ashutosh, Bhdakariya Santosh
School of Studies in Pharmaceutical Sciences, Jiwaji University, Gwalior (M.P)-474009, India

ABSTRACT

The present study aimed towards the development of active delivery system for management of hypertension. The Orodispersible tablets (ODTs) containing Telmisartan was developed in order to accomplish enhanced solubility leading to better bioavailability profile. Different ratios, of Telmisartan and PEG 6000 i.e. 1:1, 1:2, 1:3, 1:4 and 1:5 were selected for the formulation of ODT system. A batch process was adopted for the preparation of solid dispersion with each combination of drug and polymer and the finally compressed as tablets by direct compression technique. For the preformulation perspective materials were scrutinized on the basis of solubility profile, drug content, Fourier Transform Infrared (FTIR) spectroscopy and Differential scanning calorimetry (DSC). The drug polymer ratio 1:4 was selected for further compression process. The prepared batches of ODTs were characterized for micromeritic study, thickness, hardness, weight variation, wetting time, disintegration time, drug content and drug polymer ratio 1:4 was selected for further compression process. The prepared batches of ODTs were characterized for micromeritic study, thickness, hardness, weight variation, wetting time, disintegration time, drug content and in vitro drug release profile. The evaluation data for all batches was satisfactory out of them formulation TF3 containing 6% kyron T-314 showed the best results with a value of 29.3 sec and 24.1 sec for wetting and disintegration, respectively. This formulation showed superior drug release of 99.93% over a period of 30 minutes.

Keywords: Telmisartan, PEG 6000, Angioten receptor-II antagonist, Solid dispersion, Kyron T-314

INTRODUCTION

Over the years, hypertension is a mammoth challenge for the health professionals. Telmisartan is a BCS class II drug, is very poorly soluble in water, which results in the slow dissolution and hence low bioavailability when administered orally (~41%)\(^4\). The absolute bioavailability of Telmisartan is dose-dependent. The bioavailability of Telmisartan increased from 41% to 59%, when the dose was increased from 40 mg to 160 mg respectively. The solid dispersion approach can be successfully used in the improvement of solubility of poor water soluble drugs. A number of drugs have been shown to exhibit better aqueous solubility and dissolution characteristics in the form of solid dispersion\(^1\)^5. Telmisartan is used in the treatment of hypertension. The action of Telmisartan is done by binding to binding to the angiotensin II type 1 receptors, resulting in the inhibition of angiotensin II on vascular smooth muscles, so it is a angiotensin II receptor antagonist\(^6\). Problems like low solubility and bioavailability conquered by the utilization of solubility enhancement technique i.e. solid dispersion and novel formulation approach i.e. ODTs. ODTs disintegrate or dissolve very rapidly in mouth as they come into the contact with saliva, without any need of extra water. This unique asset of ODTs combines the advantages of both liquid and conventional dosage form, for oral administration. Rapid disintegration of ODTs within the oral cavity fosters pregastric absorption through buccal mucosa, pharyngeal mucosa and oesophagus. Due to this pregastric absorption first pass metabolism is bypassed and accounts for the enhanced bioavailability of the incorporated therapeutic agent. Additionally, the problem of dysphagia especially in paediatric and geriatric individuals is triumphed over by the development of ODTs\(^7\). These exceptional possessions put the ODTs on the upper hand in comparison to conventional dosage forms in terms of enhanced the patient compliance with better safety and efficacy\(^8,9\).
The present course of study attempts to enhance the solubility of Telmisartan by solid dispersion technique with polyethylene glycol (PEG 6000) and compressed it as ODT in order to develop an effective treatment for the management of Hypertension.\(^{10-12}\)

**MATERIALS AND METHODS**

**Materials**

Telmisartan was received as a gift sample from Skymap Pharmaceuticals, Roorkee, India. Sodium starch glycolate, croscarmellose sodium was a kind gift from Maple biotech pvt. Ltd. Pune, Maharashtra and kryon T-314 was kindly donated by Corel pharma chem., Ahmedabad, Gujrat. Poly ethylene glycol (PEG 6000), Micro crystalline cellulose was purchased from SD fine chemicals; Poly vinyl pyrolidone (PVP), magnesium stearate, and talc were purchased from Himedia laboratories Ltd. All other chemicals used were of analytical grade.

**Methods**

**Preparation and characterization of solid dispersion**

Solid dispersion of Telmisartan and PEG 6000 was prepared using different ratios i.e. 1:1, 1:2, 1:3, 1:4, 1:5 by conventional solvent evaporation method. Briefly, Telmisartan and PEG 6000 were weighed accurately in different ratios and mixed uniformly. This mixture was dissolved in ethanol with continuous stirring and subjected to solvent evaporation by heating at 40°C. The resultant solid dispersions were dried for 24 hr. in desiccator. Dried mass was scraped, crushed, pulverized and passed through sieve (#60).

**Solubility study**

Samples (pure drug and solid dispersion) equivalent to 10 mg of Telmisartan were added to 10 ml each of distilled water and PBS (pH 6.8). These dispersions were shaken well and kept for 24 h. The solution was filtered through whatman filter paper (#41) and spectrophotometrically analysed at 296 nm using UV-Visible spectrophotometer (UV-1800, Shimadzu, Japan).

**Infrared spectroscopy**

IR spectroscopy of Telmisartan, PEG 6000 and their solid dispersion was performed on Fourier transform infrared spectroscopy (FTIR 8400S, Shimadzu, Japan). Drug carrier and solid dispersion was mixed separately with KBr (95:5) and placed in to sample holder. The scanning range and resolution was 400-4000 cm\(^{-1}\) and 4 cm\(^{-1}\), respectively.

**Differential scanning calorimetry (DSC)**

Differential scanning calorimetry (DSC) measurements was performed for Telmisartan, PEG 6000 and its solid dispersion using DSC instrument (JADE DSC-6, PYRIS, USA) equipped with a liquid nitrogen sub ambient accessory. The instrument operated under nitrogen purge gas at a rate of 20 ml/min. Samples (3-6 mg) were weighed in open aluminium pans and scanned at a speed of 10°C/min from 30-300°C.

**Drug content analysis**

Accurately weighed quantity of solid dispersion (theoretically equivalent to 10 mg of Telmisartan) was dissolved in small amount of ethanol and volume was made up to 10 ml with PBS (pH 6.8). The solution was sonicated for 5 min. Solution was filtered through whatman filter paper (#41). The sample was assayed by UV-spectrophotometer (UV-1800, Shimadzu, Japan) at 296 nm.

**Formulation of ODTs using Solid Dispersion**

Solid dispersion of Telmisartan and PEG 6000 is compressed in to Orodispersible tablets. The TSD4 formulation containing 1:4 ratio is selected on the basis of solid dispersion characterization i.e. solubility, FTIR, DSC, and drug content for tablet preparation. Direct compression technique was utilized for the compression of solid dispersion of Telmisartan and PEG 6000 for the development of ODTs. All ingredients (solid dispersion equivalent to 20 mg Telmisartan and other excipients) were mixed properly and the blends were passed through sieve (#40). The powder blend was compressed into tablets on a single punch tablet machine using round shape flat punch having diameter of 12 mm (Rolex machineries, Mumbai, India). The tablet weight was adjusted to 200 mg (Table 1). kryon T-314, croscarmellose sodium and Sodium starch glycolate used as disintegrating agent. While microcrystalline cellulose (MCC) used as diluents and magnesium stearate was used as lubricant.

**Table 1: Composition of Various Orodispersible Tablets of Telmisartan**

<table>
<thead>
<tr>
<th>S. No.</th>
<th>Ingredients (mg)</th>
<th>Formulations</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>TF1</td>
</tr>
<tr>
<td>1.</td>
<td>Solid dispersion(Eq. to 20 mg Telmisartan)</td>
<td>100</td>
</tr>
<tr>
<td>2.</td>
<td>Kryon T-314</td>
<td>8</td>
</tr>
<tr>
<td>3.</td>
<td>Croscarmellose sodium</td>
<td>-</td>
</tr>
<tr>
<td>4.</td>
<td>Sodium starch glycolate</td>
<td>-</td>
</tr>
<tr>
<td>5.</td>
<td>Polyvinylpyrolidone (PVP)</td>
<td>10</td>
</tr>
<tr>
<td>6.</td>
<td>Microcrystalline cellulose (MCC)</td>
<td>73</td>
</tr>
<tr>
<td>7.</td>
<td>Magnesium stearate</td>
<td>4</td>
</tr>
<tr>
<td>8.</td>
<td>Talc</td>
<td>5</td>
</tr>
<tr>
<td>Total weight</td>
<td>200</td>
<td>200</td>
</tr>
</tbody>
</table>

**Evaluation of ODTs**

**Micromeric studies**

The powder mixture of formulations was characterized for their micromeric properties, such as bulk density, tapped density, compressibility index, angle of repose and hausner ratio. An accurately weighed quantity of the powder mixtures were compressed in to the graduated cylinder and volume was measured, which is called bulk volume. The graduated cylinder was closed with lid and set in to the tap density tester. The density apparatus was set for 100 tabs, noted as tapped volume.\(^{14}\).
Bulk density, tapped density, % compressibility index and hausner ratio were calculated using following formulae

\[
\text{Bulk density} = \frac{W}{V_0} \quad \text{and} \quad \text{Tapped density} = \frac{W}{V_f}
\]

Where, \(W\) = Weight of the powder \(V_0\) = Initial volume, \(V_f\) = final volume

\[
\text{Carr’s index (\%)} = \frac{(TD-BD) \times 100}{TD}
\]

Angle of repose of the powder was determined by the funnel method. It reflects the flow ability of a powder. The accurately weighed powder mixture of formulations was taken in the funnel. The height of the funnel was adjusted in such a way that the tip of funnel just touched the apex of the heap of the powder mixtures of formulations. The powder mixtures of formulations were allowed to flow through the funnel freely on to the surface. The diameter of the powder cone was measured and angle of repose was calculated using the following equation given below.

\[
	\tan \theta = \frac{h}{r}
\]

Where, \(h\) = Height of pile and \(r\) = Radius of the pile

**Thickness and hardness**

The tablet thickness was measured using digital Vernier caliper. Hardness was determined by Monsanto hardness tester (Jyoti Scientific Laboratories, Gwalior).

**Friability and weight variation**

Friability test was carried out on 10 tablets. Initial weight of the tablets was measured and subsequently placed in chamber of friabilator (Roche friabilator) at 25 rpm speed for 4 min. After that tablets were de-dusted, reweighed and % friability was calculated. From each batch twenty tablets weight were noted using electronic balance. Their average weight (\(W_A\)) was calculated. Percentage weight variation and average weights of the tablets along with standard deviation values were calculated using formulae given below.

\[
\text{% Weight variation} = \frac{(W_A - W_f)}{W_A} 
\]

**Wetting time**

Another important parameter is wetting time. Five circular tissue papers of 10 cm diameter were placed in a Petri dish of a 10 cm diameter. 10 ml of water containing eosin, a water soluble dye, was added to Petri dish. A tablet was carefully placed on the surface of the tissue paper. The time required for water to reach upper surface of the tablet is noted as wetting time.\[15\]

**Disintegration time**

Disintegration test is determined using the USP device used to test disintegration comprises six glass tubes that are 3" long, open at the top, and held against 10" screen at the bottom end of the basket rack assembly. One tablet is placed in each tube and the basket rack is positioned in beaker containing 900 ml of PBS (pH 6.8) at 37±2°C, such that the tablets remain below the surface of the liquid on their upward movement and descend not closer than 2.5cm from the bottom of the beaker. The disintegration time was recorded at the point at which tablet completely disintegrated.

**Drug content**

Ten tablets were weighed and powdered. An amount of the powder equivalent to 10 mg of Telmisartan was dissolved in 100 ml of pH (6.8) phosphate buffer, filtered, diluted suitably and analyzed for drug content at 296 nm using UV Visible spectrophotometer (UV-1800, Shimadzu, Japan)\[16\].

**In vitro drug release study and Release kinetics**

In vitro drug release studies of all formulations were carried out using paddle type tablet dissolution test apparatus (USP XXII type) at 50 rpm. The dissolution medium, phosphate buffer pH (6.8) was maintained at 37.0±0.5°C. Samples were withdrawn at different intervals, diluted suitably and analyzed at 296 nm for cumulative drug release using UV-Visible spectrophotometer (UV-1800, Shimadzu, Japan). The percentage of Telmisartan dissolved from tablet was calculated and the graph was plotted by time Vs % of drug dissolved.\[16\]

The in vitro drug release data is fitted to various release kinetic models like zero order, first order, Higuchi matrix, Hixson- crowell and KorseMeyer- Peppas kinetic model. The coefficient of correlation (R²) values were calculated from the regression analysis of above plots.

**RESULTS AND DISCUSSION**

**Solubility study**

The solubility of pure drug in water was found to be 0.056 mg/ml which suggest that Telmisartan is practically insoluble in water; hence shows lower bioavailability. In present study solid dispersion of Telmisartan is prepared with PEG 6000 in ratios 1:1, 1:2, 1:3, 1:4, 1:5. The solubility of these dispersions were found 4.21, 7.91, 15.62, 22.38, 19.46 mg/ml and 9.65, 13.66, 19.21, 28.67, 22.42 mg/ml in distilled water and PBS (pH 6.8) respectively. Result suggests that solubility of Telmisartan is increased with respect to the concentration of PEG 6000 till 1:4 and it started decreasing thereafter.

**Infrared spectroscopy**

The FTIR studies were carried out to investigate the possible interaction between the Telmisartan and PEG 6000 in the solid dispersion formulation. The FTIR spectra of pure drug, PEG 6000, and its solid dispersion shows no possible interaction between drug and carrier, which confirms the stability of drug in its solid dispersion. Solid dispersion brings characteristic change in the Telmisartan from crystalline to amorphous by dispersing in PEG 6000, which leads to solubility enhancement and improvements of flow properties.
Differential scanning calorimetry (DSC)

Differential scanning calorimetry (DSC) measurements were performed on Telmisartan, PEG 6000, and its solid dispersion using a DSC (JADE DSC-6, PYRIS, USA) to analyse the thermal behaviour. The DSC thermogram of Telmisartan exhibited (fig. 2) an endothermic peak at 263°C, which corresponds to the melting point of the Telmisartan. The carrier PEG 6000 showed an endothermic peak at 63.06°C, which corresponds to the melting point of PEG 6000. There were only one endothermic peak observed for solid dispersion prepared using drug:carrier 1:4 at 58.06°C. The disappearance of endothermic peak of Telmisartan in solid dispersion gives an idea that Telmisartan might be dissolve state in melted PEG 6000. Solid dispersion shows weakness of endothermic peak at the melting point of drug. This could be attributed to higher PEG 6000 concentration and uniform distribution of drug in the crust of PEG 6000 resulting in complete miscibility of molten drug in PEG 6000. The disappearance of endothermic peak in solid dispersion formulations confirms the amorphous state of drug in prepared solid dispersion formulations.

Figure 2: Fourier transform infrared (FTIR) spectra of Telmisartan, PEG 6000, and solid dispersion

Figure 3: Differential scanning calorimetry (DSC) thermogram of Telmisartan, PEG 6000, and solid dispersion
Drug content analysis

Percentage drug content of various solid dispersion formulations i.e. TSD1, TSD2, TSD3, TSD4, and TSD5 were found to be 92.94±0.48%, 94.35±0.57%, 96.78±0.78%, 98.34±0.76%, and 96.62±0.87% respectively. The percentage drug content found 100±5% for all solid dispersion formulations. It was graphically represented in fig. 4.

Figure 4: % Drug content of solid dispersion

Formulation of ODTs using solid dispersion

From above study of solid dispersion preparation of Telmisartan with PEG 6000 it was found that solid dispersion ratio TSD4 (1:4) has maximum solubility and drug content, is selected for further preparation of ODTs with addition of Superdisintegrants i.e. kyron T-314, croscarmellose sodium and sodium starch glycolate, taken in various ratios to find the optimum concentration of the Superdisintegrants required to yield formulation having least wetting time and disintegration time.

Evaluation of ODTs

Micromeritic studies

Micromeritic properties of powder reflect the appropriateness of formulation. Hence, micromeritic properties of the drug excipients mixture were studied in term of bulk density, tapped density, car’s index and angle of repose to establish the flow property. The car’s index of all the formulations was found to be in the range from 15.15 % to 20.58%. The hausner’s ratio was found to be in the range from 1.17 to 1.25 (i.e. less than 1.25) which indicates good flow properties. Angle of repose was found to be 25.76 to 30.21 degree (Table 2). The micromeritic properties of pure drug doesn’t show the free flow of powder for compression but when the solid dispersion of the Telmisartan is prepared with PEG 6000 and mixed with other excipients and evaluated for micromeritic properties shows free flow ability and compressibility for direct compression. PEG 6000 alters the particle size and shape of drug particles from crystalline to spherical resulting in enhancement of flow ability and compressibility.

Table 2: Micromeritic Studies of Various Powder Blend Formulations

<table>
<thead>
<tr>
<th>Batch</th>
<th>Angle of repose</th>
<th>Bulk density</th>
<th>Tapped density</th>
<th>%Compressibility</th>
<th>Hausner ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>TF1</td>
<td>26.99±1.71</td>
<td>0.54±0.06</td>
<td>0.68±0.07</td>
<td>20.58±1.10</td>
<td>1.25±0.01</td>
</tr>
<tr>
<td>TF2</td>
<td>26.23±1.50</td>
<td>0.54±0.02</td>
<td>0.65±0.02</td>
<td>19.40±1.31</td>
<td>1.24±0.08</td>
</tr>
<tr>
<td>TF3</td>
<td>25.76±0.22</td>
<td>0.56±0.06</td>
<td>0.67±0.05</td>
<td>16.41±1.20</td>
<td>1.19±0.08</td>
</tr>
<tr>
<td>TF4</td>
<td>27.06±1.71</td>
<td>0.54±0.04</td>
<td>0.67±0.04</td>
<td>16.92±0.41</td>
<td>1.20±0.03</td>
</tr>
<tr>
<td>TF5</td>
<td>28.91±0.20</td>
<td>0.57±0.09</td>
<td>0.69±0.07</td>
<td>17.39±0.98</td>
<td>1.21±0.02</td>
</tr>
<tr>
<td>TF6</td>
<td>30.21±0.01</td>
<td>0.50±0.04</td>
<td>0.62±0.03</td>
<td>19.35±1.24</td>
<td>1.24±0.07</td>
</tr>
<tr>
<td>TF7</td>
<td>30.05±0.98</td>
<td>0.51±0.01</td>
<td>0.62±0.01</td>
<td>17.74±0.71</td>
<td>1.17±0.02</td>
</tr>
<tr>
<td>TF8</td>
<td>29.53±0.21</td>
<td>0.56±0.04</td>
<td>0.66±0.06</td>
<td>18.03±0.28</td>
<td>1.22±0.07</td>
</tr>
<tr>
<td>TF9</td>
<td>29.21±0.56</td>
<td>0.50±0.02</td>
<td>0.61±0.09</td>
<td>18.03±0.28</td>
<td>1.22±0.07</td>
</tr>
</tbody>
</table>

Values are expressed as mean ± S.D., n=3

Thickness and hardness

All the prepared tablets are characterized by their size and shape, which found round shape and uniform thickness in the range of 3.36 to 3.85 mm. The hardness of formulations was found within the range of 4.12 to 4.48 kg/cm².

Friability and weight variation

Friability for all formulations was found to be less than 1%. This is the acceptable limit. The result shows resistance to loss of weight indicated the tablet ability to withstand abrasion in handling, packaging and shipment.

The weight variation of tablets was determined according to the specification in USP and all the tablets were found to comply with specification. Weight of the tablets was found in the range of (±5%) variation.

Wetting time

Wetting time for ODTs depends on the concentration of Superdisintegrants. We have used three types of Superdisintegrants i.e. kyron T-314, croscarmellose sodium and sodium starch glycolate in the concentration range of 4% to 6%. The wetting time for all formulations was 40.6 to 29.3 sec for kyron T-314 containing formulation, 59.1 to 49.9 sec for croscarmellose sodium containing formulation, and 66.1 to 58.3 sec for sodium starch glycolate containing formulation. The least wetting time amongst all formulation is found with TF3 formulation which contains 6% kyron T-314. Kyron T-314 is a crosslinked polymer of Polycarboxylic acids breaks the tablets into very smaller particles, thus it increases the effective surface area for the absorption of the active substances and ultimately it increases the dissolution and bioavailability of the active substances. Its 4.0% to 6.0% quantity is sufficient for dissolution improvement and suitable for direct compression. It also provide smooth cream-like mouth feel, so more suitable for ODTs. All the results of wetting time of all formulations are shown in table 3. This has a very high swelling tendency of hydration either in contact with water or G.I. fluids causing very fast wetting of the tablets.
Figure 5: Wetting and disintegration time of various Orodispersible tablets prepared

Disintegration time

Another fact for ODTs which is much more important is disintegration time of the tablets. According to European pharmacopoeia ODTs required less than 3 minute in disintegration. In the present study, all the tablets disintegrated in approximately in 1 minute. Disintegration time for all formulations was found between 28.8 to 24.1 sec for kyon T-314 containing formulation, 52.8 to 61.1 sec for croscarmellose sodium containing formulation, and 56.3 to 38.3 sec for sodium starch glycolate containing formulation (Table 3). In amongst all Superdisintegrants kyon T-314 show faster disintegration time for tablets (for TF3 24.1 sec) this is because it has a very high swelling tendency of hydration either in contact with water or G.I. fluids causing fast disintegration without the formation of lumps and thus acts as an effective tablet Superdisintegrant. The porous structure of the tablets is responsible for faster water uptake resulting in fast disintegration.

Table 3: Evaluation Parameters of Various Orodispersible Tablets

<table>
<thead>
<tr>
<th>Batch</th>
<th>Friability (%)</th>
<th>Wetting time (sec)</th>
<th>Disintegration time (sec)</th>
<th>% Drug content</th>
</tr>
</thead>
<tbody>
<tr>
<td>TF1</td>
<td>0.82±0.67</td>
<td>40.6±2.22</td>
<td>28.8±1.89</td>
<td>96.82±0.51</td>
</tr>
<tr>
<td>TF2</td>
<td>0.62±0.68</td>
<td>36.0±3.30</td>
<td>26.2±1.90</td>
<td>98.21±0.78</td>
</tr>
<tr>
<td>TF3</td>
<td>0.52±0.94</td>
<td>29.3±1.01</td>
<td>24.1±0.90</td>
<td>99.67±0.27</td>
</tr>
<tr>
<td>TF4</td>
<td>0.69±0.21</td>
<td>59.1±1.02</td>
<td>53.1±1.22</td>
<td>97.61±0.82</td>
</tr>
<tr>
<td>TF5</td>
<td>0.83±0.73</td>
<td>53.2±0.08</td>
<td>42.3±2.22</td>
<td>95.61±0.10</td>
</tr>
<tr>
<td>TF6</td>
<td>0.69±0.83</td>
<td>49.9±6.2</td>
<td>36.1±0.45</td>
<td>98.24±0.36</td>
</tr>
<tr>
<td>TF7</td>
<td>0.72±0.93</td>
<td>66.1±1.78</td>
<td>52.8±0.34</td>
<td>96.45±0.92</td>
</tr>
<tr>
<td>TF8</td>
<td>0.66±0.41</td>
<td>61.8±0.51</td>
<td>50.0±1.41</td>
<td>97.81±0.30</td>
</tr>
<tr>
<td>TF9</td>
<td>0.59±0.01</td>
<td>58.3±0.22</td>
<td>61.1±1.92</td>
<td>96.67±0.60</td>
</tr>
</tbody>
</table>

Values are expressed as mean ± S.D., n=3

Drug content

Percentage drug content for various formulations i.e. TF1, TF2, TF3, TF4, TF5, TF6, TF7, TF8, TF9 were found to be 96.82%, 98.21%, 99.67%, 97.61%, 95.61%, 98.24%, 96.45%, 97.81%, 96.67% respectively. The percentage drug content was found to be in the USP limits for all formulations. The % drug content for all formulations is represented in table 3.
In vitro drug release study

The release characteristics of ODTs was studied using tablet dissolution test apparatus is paddle type (USP XXII type) at 50 rpm. 900 ml of Phosphate buffer pH (6.8) was used as the dissolution media at 37.0±2°C. The cumulative percentage drug release of formulations i.e. TF1, TF2, TF3, TF4, TF5, TF6, TF7, TF8, TF9 were 97.72%, 96.92%, 99.93%, 95.82%, 92.87%, 89.01%, 90.56%, 93.81%, 95.28% respectively in 30 minute. All the results of Cumulative percentage drug release of all formulations graphically represented in fig. 7. Formulation TF3 containing kyron T-314 shows better drug release profile 99.93%.

The in-vitro drug release profile of various optimized formulations were studied for release kinetics with respect to zero order, first order, Higuchi, Hixson Crowell and Korsemeyer-peppas model (Table 4). The R² for various kinetics models for optimized formulation TF3 was found 0.999, 0.654, 0.988, 0.972, 0.968 respectively which is closer to one, partially for Zero order model is very close to one. The diffusional exponent, n characterizes the mechanism of drug release. It is known that for non-swelling tablets, the drug release can generally be expressed by the Fickian diffusion mechanism, for which n = 0.5. For non-Fickian release, the n value falls between 0.5 and 1.0 (0.5 < n < 1.0); whereas in the case super case II transport n >1. The value of n for all formulations is in the range from 0.151 to 0.516. Which conclude that all formulation follow fickian diffusion mechanism.
CONCLUSION
The method utilized for the preparation of ODTs was simple and reproducible. ODTs of Telmisartan prepared with addition of solid dispersion technique by solvent evaporation method with PEG 6000 and Superdisintegrants like kyron T-314, croscarmellose sodium and sodium starch glycolate. Formulation containing 6% of Kyron T-314 shows least wetting time and disintegration time. Which indicates that kyron T-314 is suitable disintegrant for ODTs.

The results of the study establish the Telmisartan ODTs as a potential drug delivery system for effective management of hypertension with improved patient compliance.

CONFLICT OF INTEREST
The authors confirm that this article content has no conflict of interest.

REFERENCES
The authors confirm that this article content has no conflict of interest.